Obstructive Sleep Apnea (OSA)

Obstructive sleep apnea (OSA)

Obstructive sleep apnea is estimated to affect roughly 1.5 billion adults worldwide. It is strongly linked to higher risk of hypertension, heart failure, arrhythmias, coronary artery disease, stroke, metabolic syndrome, type 2 diabetes, depression, cancer, and other chronic conditions —and may shorten life expectancy when left unaddressed.

Untreated OSA strains quality of life (including relationships and daytime alertness), increases errors at work and the risk of road accidents, and drives substantial healthcare spending. Early, appropriate therapy can help avoid complication-related costs that in some analyses reach on the order of US$153,477 per year for related care.

Intelligent positive airway pressure therapy with ergonomically designed CPAP masks, combined with remote monitoring and support, can improve sleep experience, comfort, and long-term adherence —helping people sustain healthier routines and confidence over time.

Clinical evidence

Reliable therapeutic pressure and a well-fitting, comfortable mask are central to how users experience CPAP therapy. Continuous, automatically tailored pressure levels; humidified airflow without nasal congestion; and ergonomic, discreet mask designs that reduce feelings of stuffiness or claustrophobia can improve comfort, satisfaction, and adherence.

View clinical evidence
Clinical context for obstructive sleep apnea therapy

Value proposition

When IoT and telehealth connect users to timely therapy feedback, professional guidance, and self-management tools, satisfaction and confidence in CPAP therapy can rise —along with adherence. Remote support can also reduce unnecessary clinic visits, travel, and time away from work compared with traditional follow-up alone.

Connected care and value of telehealth for sleep therapy

Related products

1 / 5
WiZARD 320 full face mask

WiZARD 320

References

  1. Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pépin JL, Peppard PE, Sinha S, Tufik S, Valentine K, Malhotra A. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019 Aug;7(8):687-698. doi: 10.1016/S2213-2600(19)30198-5. Epub 2019 Jul 9. PMID: 31300334; PMCID: PMC7007763.
  2. Arredondo E, Udeani G, Panahi L, Taweesedt PT, Surani S. Obstructive Sleep Apnea in Adults: What Primary Care Physicians Need to Know. Cureus. 2021 Sep 9;13(9):e17843. doi: 10.7759/cureus.17843. PMID: 34660049; PMCID: PMC8501746.
  3. Knauert M, Naik S, Gillespie MB, Kryger M. Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome. World J Otorhinolaryngol Head Neck Surg. 2015 Sep 8;1(1):17-27. doi: 10.1016/j.wjorl.2015.08.001. PMID: 29204536; PMCID: PMC5698527.
  4. Streatfeild J, Hillman D, Adams R, Mitchell S, Pezzullo L. Cost-effectiveness of continuous positive airway pressure therapy for obstructive sleep apnea: health care system and societal perspectives. Sleep. 2019 Dec 24;42(12):zsz181. doi: 10.1093/sleep/zsz181. PMID: 31403163.
  5. Gonzaga C, Bertolami A, Bertolami M, Amodeo C, Calhoun D. Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens. 2015 Dec;29(12):705-12. doi: 10.1038/jhh.2015.15. Epub 2015 Mar 12. PMID: 25761667.
  6. Borel JC, Tamisier R, Dias-Domingos S, Sapene M, Martin F, Stach B, Grillet Y, Muir JF, Levy P, Series F, Pepin JL; Scientific Council of The Sleep Registry of the French Federation of Pneumology (OSFP). Type of mask may impact on continuous positive airway pressure adherence in apneic patients. PLoS One. 2013 May 15;8(5):e64382. doi: 10.1371/journal.pone.0064382. PMID: 23691209; PMCID: PMC3654912.
  7. Isetta V, Negrín MA, Monasterio C, Masa JF, Feu N, Álvarez A, Campos-Rodriguez F, Ruiz C, Abad J, Vázquez-Polo FJ, Farré R, Galdeano M, Lloberes P, Embid C, de la Peña M, Puertas J, Dalmases M, Salord N, Corral J, Jurado B, León C, Egea C, Muñoz A, Parra O, Cambrodi R, Martel-Escobar M, Arqué M, Montserrat JM; SPANISH SLEEP NETWORK. A Bayesian cost-effectiveness analysis of a telemedicine-based strategy for the management of sleep apnoea: a multicentre randomised controlled trial. Thorax. 2015 Nov;70(11):1054-61. doi: 10.1136/thoraxjnl-2015-207032. Epub 2015 Aug 26. PMID: 26310452.